X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VG901 is an intravitreally administered, CNGA1 gene transfering, cell and gene therapy drug candidate, which is currently being evaluated for the treatment of retinitis pigmentosa.
Lead Product(s): VG901
Therapeutic Area: Genetic Disease Product Name: VG901
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases.
Lead Product(s): vgAAV.GL
Therapeutic Area: Ophthalmology Product Name: vgAAV.GL
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 26, 2022
Details:
Under the terms of collaboration, Regeneron and ViGeneron will create and validate vgAAV-based therapeutic candidates including VG801, for one undisclosed IRD target. Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target.
Lead Product(s): VG801
Therapeutic Area: Genetic Disease Product Name: VG801
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 06, 2022
Details:
The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.
Lead Product(s): VG801
Therapeutic Area: Ophthalmology Product Name: VG801
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2021
Details:
WuXi ATU will accelerate the development of VG901 by manufacturing, testing and making available the clinical trial grade treatment while leveraging its trusted, world-class AAV Suspension and Plasmid DNA platforms.
Lead Product(s): VG901
Therapeutic Area: Genetic Disease Product Name: VG901
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: WuXi Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
